This trial motivated the acceptance of pyrotinib by the China Food and Drug Administration (CFDA) for advanced breast cancer treatment, and based on its remarkable antitumor efficacy in HER2-positive breast cancer patients, we evaluated its application for the treatment of HER2-positive GC in the present study. This evidence concerns the gene ERBB2 and breast cancer.